New RAS Inhibitor Shows Promise Against Hard-to-Treat Bile Duct Cancer
A next-gen RAS inhibitor called daraxonrasib targets KRAS-mutant cholangiocarcinoma, showing strong preclinical results and early clinical activity.
Summary
About one in four bile duct cancers (cholangiocarcinoma) carry KRAS mutations, making them difficult to treat with existing therapies. Researchers tested a new class of drugs called RAS(ON) multi-selective inhibitors, which block the active form of RAS proteins regardless of the specific mutation. In lab models and animal studies, these inhibitors produced strong anti-tumor effects. Notably, two patients with advanced KRAS-mutant cholangiocarcinoma showed clinical responses to daraxonrasib, a drug in this class. The inhibitors also worked better when combined with standard chemotherapy regimens. The study additionally mapped out how tumors develop resistance, finding that most resistance mechanisms involve reactivating the same RAS signaling pathway. These findings suggest KRAS-mutant cholangiocarcinoma is heavily dependent on RAS signaling and that targeting it could be a viable treatment strategy.
Detailed Summary
Cholangiocarcinoma (CCA), or bile duct cancer, is an aggressive malignancy with limited treatment options and poor survival rates. Approximately 25% of CCA tumors harbor activating KRAS mutations, which historically have been considered undruggable. The emergence of RAS(ON) multi-selective inhibitors — drugs that block RAS in its active, GTP-bound state — represents a significant shift in the ability to target this oncogene.
This study investigated whether RAS(ON) multi-selective inhibitors could suppress tumor growth in KRAS-mutant CCA. Researchers used a range of preclinical models including cell-derived xenografts, patient-derived xenografts, and immunocompetent allograft models to evaluate efficacy. These diverse model systems provide a more comprehensive picture of drug activity than any single approach alone.
The results were encouraging across all preclinical settings, with strong anticancer responses observed. Critically, the researchers also reported clinical activity of daraxonrasib — a RAS(ON) multi-selective inhibitor — in two patients with advanced KRAS G12-mutant CCA, providing early proof-of-concept in humans. Additionally, combining RAS-GTP inhibition with standard-of-care chemotherapy regimens prolonged survival in both human xenograft and mouse allograft models, suggesting potential synergy.
The study also examined resistance mechanisms, finding that both intrinsic and acquired resistance predominantly involved pathways that reactivate RAS signaling, pointing to rational combination strategies to overcome resistance. This insight is clinically valuable as it may guide future trial designs.
Several caveats temper enthusiasm. The clinical data involves only two patients, which is insufficient to draw broad conclusions about efficacy or safety. Conflicts of interest exist, as several authors are employees of Revolution Medicines, the company developing daraxonrasib. The full paper was not accessible for this review, limiting depth of analysis. Nonetheless, these findings strongly support formal clinical trials of RAS-GTP inhibition in KRAS-mutant CCA.
Key Findings
- RAS(ON) multi-selective inhibitors produced strong anti-tumor effects across multiple preclinical CCA models.
- Daraxonrasib showed clinical activity in two patients with advanced KRAS G12-mutant cholangiocarcinoma.
- Combining RAS-GTP inhibition with standard chemotherapy prolonged survival in xenograft and allograft models.
- Resistance to RAS(ON) inhibitors primarily involves reactivation of RAS signaling, suggesting targetable mechanisms.
- Roughly 25% of CCA tumors carry KRAS mutations, defining a substantial patient population for this approach.
Methodology
The study used cell-derived xenografts, patient-derived xenografts, and immunocompetent allograft mouse models to evaluate RAS(ON) inhibitor efficacy in KRAS-mutant CCA. Clinical observations were reported for two patients with advanced disease treated with daraxonrasib. Resistance mechanisms were characterized through preclinical modeling of intrinsic and acquired resistance.
Study Limitations
Clinical evidence is limited to only two patients, making it impossible to draw conclusions about efficacy, safety, or generalizability. Several co-authors are employees and stockholders of Revolution Medicines, the developer of daraxonrasib, representing a significant conflict of interest. This summary is based on the abstract only, as the full paper was not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.